September 25, 2024
TOPLINE: In patients with rectal cancer, having persistent lymph node metastases after neoadjuvant chemoradiotherapy is associated with worse overall survival outcomes and higher rates of recurrence […]
September 24, 2024
TOPLINE: Patients with breast cancer carrying TP53 pathogenic variants face an 8.8% cumulative risk for developing sarcoma within 15 years of receiving radiotherapy. However, the 10-year […]
September 24, 2024
BARCELONA, Spain — Over three decades, from 1990 to 2019, the global incidence of early-onset cancer (EOC) increased by 79.1%. Irit Ben-Aharon, MD, PhD, from the […]
September 24, 2024
The US Food and Drug Administration (FDA) has issued a draft guidance aimed at ensuring that international trials for oncology drug approvals apply to US patients […]
September 24, 2024
BARCELONA, SPAIN — Not all patients with colorectal cancer are the same, and more research is needed to examine differences between patients according to their sex, […]
September 23, 2024
Despite the “remarkable progress” in cancer research and care, cancer remains “an ongoing public health challenge,” which requires significant attention and funding, according to the Cancer […]
September 23, 2024
TOPLINE: Medicare Advantage plans had lower adjusted total resource use than traditional Medicare for patients with cancer undergoing chemotherapy, with no difference in 18-month survival between […]
September 23, 2024
TOPLINE: Black women in the United States have higher breast cancer (BC) mortality rates than White women across tumor subtypes. The greatest disparity in BC-specific survival […]
September 23, 2024
The Food and Drug Administration expanded the label of isatuximab-irfc (Sarclisa — Sanofi-Aventis) on September 20 to include treatment with bortezomib, lenalidomide, and dexamethasone for newly […]